Abstract:Vutrisiran demonstrated beneficial effects on N‐terminal prohormone of brain‐type natriuretic peptide (NT‐proBNP) and other prespecified exploratory echocardiographic parameters versus external placebo in both a modified intent‐to‐treat (mITT) population and a cardiac subpopulation at Month 18. In a planned cohort undergoing 99mTc scintigraphy assessments, a majority of vutrisiran‐treated patients experienced reduced or stabilized radiotracer uptake versus baseline. Vutrisiran demonstrated evidence of potential benefit on cardiac manifestations in patients with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy, and an acceptable safety profile, including no cardiac safety concerns. CI, confidence interval; LV, left ventricular; Q3M, every 3 months; SC, subcutaneous. aIn a planned cohort. AimsHELIOS‐A was a Phase 3, open‐label study of vutrisiran, an RNA interference therapeutic, in patients with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy. This analysis evaluated vutrisiran's impact on exploratory cardiac endpoints in HELIOS‐A patients. Methods and resultsPatients were randomized 3:1 to subcutaneous vutrisiran 25 mg every 3 months or intravenous patisiran 0.3 mg/kg every 3 weeks (reference group) for 18 months. Exploratory cardiac endpoints included change from baseline in N‐terminal prohormone of brain‐type natriuretic peptide (NT‐proBNP) and echocardiographic parameters versus external placebo (APOLLO study). The modified intent‐to‐treat (mITT) population comprised randomized patients receiving any study drug (n = 122). A cardiac subpopulation with evidence of cardiac amyloid involvement (n = 40) was prespecified. 99mTc scintigraphy exploratory assessments in a planned vutrisiran‐treated cohort at select sites were compared with baseline. At Month 18, vutrisiran demonstrated beneficial effects on NT‐proBNP versus external placebo in the mITT and cardiac subpopulations (adjusted geometric mean fold change ratio [95% confidence interval] 0.480 [0.383–0.600], p = 9.606 × 10−10 and 0.491 [0.337–0.716], p = 0.0004, respectively). Benefits or trends towards benefit in echocardiographic parameters versus external placebo were observed for both populations. In 99mTc scintigraphy assessments, 32/47 (68.1%) and 31/48 (64.6%) patients exhibited reduced normalized left ventricular total uptake and heart‐to‐contralateral lung ratio, respectively. Perugini grade was reduced or unchanged versus baseline in 55/57 (96.5%) evaluable patients. No increase in cardiac adverse events was observed with vutrisiran versus external placebo. ConclusionsVutrisiran demonstrated evidence of potential benefit on cardiac manifestations in patients with ATTRv amyloidosis with polyneuropathy, with an acceptable safety profile.

Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study

Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin‐mediated amyloidosis with polyneuropathy

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Outpatient Worsening Heart Failure in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial

Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis

Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects

Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review

Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen

A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy

Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation

Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy

Benefit of vutrisiran in transthyretin amyloidosis with cardiomyopathy

137 PRIMARY RESULTS FROM APOLLO-B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY

Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis

2020 Peripheral Nerve Society Virtual Event

Real‐life experience with disease‐modifying drugs in hereditary transthyretin amyloid polyneuropathy: A clinical and electrophysiological appraisal

Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health‐Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis

Efficacy and safety of patisiran for ATTRv-PN: a systematic review and meta-analysis

Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis

Left Ventricular Deformation and Myocardial Work Parameters in Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran: A Single-Center Study

Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis